
EGFRm NSCLC after osimertinib: How should we weigh PFS when OS is not statistically significant? Recent HAS & FDA decisions on amivantamab and ivonescimab raise a key question: Is delaying progression enough?clinical benefit? Final OS curves from MARIPOSA-2 attached. #LungCancer
































